TRU-SENTIMENT · DeltaNeutral
TNGX Trading Analysis - 11/20/2026 01:10 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
TNGX (Tango Therapeutics Inc.) at $22.07. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $590 vs put $1,085,800. RSI 51.1.
- Symbol
- TNGX
- Price
- $22.07
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-20 13:10:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From embedded True Sentiment (2026-11-20 13:09):
Call Volume: $590 (0.1%) Put Volume: $1,085,800 (99.9%) Total: $1,086,390
Sentiment: Bearish. 1 call contract vs 1,246 put contracts (7 put trades). Pure directional conviction strongly favors puts. This diverges from neutral RSI / mild bearish MACD — options flow is far more bearish than tape suggests, implying institutional hedge or directional bet lower.
Key Statistics: TNGX
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-1.37 |
| Market cap | $3.73B |
| Shares outstanding | 169.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.99 |
| 52-week low | $8.30 |
| 52-week high | $34.39 |
| Historical volatility | 95.9% |
Ownership & trading
| Institutional ownership | 47.2% |
| Average daily volume | 3.8M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge of TNGX (Tempus Therapeutics / oncology biotech) and are separated from the data-driven analysis below:
- Recent pipeline updates from TNGX highlighted interim Phase 1/2 data for its lead solid-tumor asset, with mixed efficacy signals that triggered volatility.
- Biotech sector re-rating on FDA guidance changes has pressured small-cap namics with negative EPS, including TNGX.
- No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01, suggesting annual filing season risk.
- General context: high historical volatility (95.92%) aligns with binary catalyst profile typical of pre-revenue oncology names.
Context vs data: Heavy put-dollar volume in options flow (99.9% puts) may reflect hedging into undefined pipeline/regulatory events rather than pure directional collapse.
Fundamental Analysis
Based strictly on embedded FUNDAMENTALS (2026-11-20):
- Trailing EPS is -1.37; company is unprofitable with no trailing PE (null) and no forward PE (null).
- Revenue, margins, ROE, and FCF are null — no disclosed profitability or growth metrics in data.
- Market cap 3.73B; shares out 169.46M; institutional ownership 47.21%.
- Dividend yield 0.0%; beta 0.99 (market-aligned).
- 52-week range 8.30 to 34.39; current price 22.79 sits mid-range.
- Historical volatility 95.92% — extreme; average volume 3.80M.
- No analyst target or recommendation key provided (null).
Fundamentals show a pre-revenue, loss-making biotech with negative EPS and undefined margins. This diverges from any trend-following technical strength and supports a sentiment backdrop where options flow is heavily defensive (puts).
Current Market Position
Current price per indicators: 22.79 (2026-11-19 close). Minute bars show 2026-11-20 12:40 last close 22.07, drifting from 22.98 open on 11-19 09:30 to 22.00 low by 12:20 before minor bounce to 22.20 and fade.
Daily history: 11-17 close 22.32, 11-18 close 22.02, 11-19 close 22.79 (intraday high 23.66, low 22.09, vol 1.27M).
Intraday momentum: lower highs from 22.98 to 22.07 across two sessions; volume tapering (last bar 17,925 vs 29,489 at 09:50 11-19).
Technical Analysis
Technical Indicators
SMA alignment: 50 (23.51) > 5 (23.34) > 20 (23.11); price 22.79 below all three — bearish stack. No golden cross; mild bearish displacement.
RSI 51.06 = neutral momentum, no extremes. MACD -0.05 below signal -0.04, hist -0.01 = subtle bearish momentum. Bollinger mid 23.11, price below mid, within bands (20.63–25.60) = no squeeze/expansion signal. 30-day range high 27.65, low 20.74; price at 22.79 = 26.3% above low, 17.5% below high.
True Sentiment Analysis (Delta 40-60 Options)
From embedded True Sentiment (2026-11-20 13:09):
Call Volume: $590 (0.1%) Put Volume: $1,085,800 (99.9%) Total: $1,086,390
Sentiment: Bearish. 1 call contract vs 1,246 put contracts (7 put trades). Pure directional conviction strongly favors puts. This diverges from neutral RSI / mild bearish MACD — options flow is far more bearish than tape suggests, implying institutional hedge or directional bet lower.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.